Prothena price target lowered to $81 from $83 at JMP Securities

JMP Securities lowered the firm’s price target on Prothena to $81 from $83 and keeps an Outperform rating on the shares. Prothena reported Q3 results ahead of consensus estimates and reiterated that the Phase 1 SAD/MAD results for amyloid-beta antibody, PRX012, remain on track to be announced by the end of the year, the analyst tells investors in a research note.